Astellas: FDA Advisory Panel Did Not Back Approval of Tivozanib

Astellas Pharma said on May 7 that an advisory panel to the US FDA did not support approval of tivozanib, a vascular endothelial growth factor receptor 1, 2, and 3 inhibitor developed jointly with US partner AVEO Oncology, for the...read more